VERTEX PHARMACEUTICALS INCVRTX

Market cap

$109.6B

P/E ratio

	Dec 31, 2010	Dec 31, 2011	Dec 31, 2012	Dec 31, 2013	Dec 31, 2014	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Cash and cash equivalents	243	475	489	569	625	715	1,184	1,665	2,650	3,109	5,988	6,795	10,504	10,369	4,570
Marketable securities	788	494	832	896	762	328	251	847	1,036	699	671	730	275	849	1,546
Accounts receivable, net	13	183	143	86	76	178	201	281	410	634	885	1,137	1,442	1,563	1,609
Inventories	-	112	30	14	31	57	78	112	124	168	281	353	461	739	1,205
Prepaid expenses and other current assets	13	15	25	24	53	51	71	166	141	214	308	546	554	624	666
Total current assets	1,057	1,331	1,590	1,589	1,547	1,407	1,832	2,649	3,843	4,823	8,133	9,561	13,235	14,144	9,596
Property and equipment, net	-	-	-	-	-	-	-	-	-	-	959	1,094	1,108	1,159	1,228
Goodwill	26	31	31	31	40	50	50	50	50	1,000	1,000	1,000	1,100	1,100	1,100
Other intangible assets, net	-	-	-	-	-	-	-	-	-	400	400	400	604	840	826
Deferred tax assets	-	-	-	-	-	-	-	-	-	1,191	883	935	1,247	1,812	2,331
Operating lease assets	-	-	-	-	-	-	-	-	-	-	326	330	347	294	1,357
Long-term marketable securities	-	-	-	-	-	-	-	-	-	-	-	-	-	2,498	5,108
Other assets	17	11	10	2	3	7	12	8	41	158	49	111	522	895	999
Total assets	1,725	2,204	2,759	2,319	2,335	2,499	2,897	3,546	6,246	8,318	11,752	13,433	18,151	22,730	22,533
Accounts payable	36	75	101	49	71	75	61	74	111	88	155	195	304	365	413
Accrued expenses	134	252	265	271	210	306	315	444	604	1,117	1,405	1,679	2,127	2,655	2,789
Other current liabilities	6	-	20	25	5	14	11	27	41	130	317	268	312	527	363
Total current liabilities	475	392	433	398	368	506	793	807	1,120	1,335	1,878	2,142	2,742	3,547	3,565
Long-term operating lease liabilities	-	-	-	-	-	-	-	-	-	-	350	377	380	349	1,544
Long-term finance lease liabilities	-	-	-	-	-	-	-	-	-	539	539	510	431	376	113
Other long-term liabilities	-	7	14	12	22	32	102	26	26	183	108	117	686	878	902
Total liabilities	1,221	1,239	1,525	963	1,238	1,405	1,559	1,504	1,811	2,233	3,065	3,333	4,238	5,150	6,124
Commitments and contingencies	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preferred Stock, Value, Issued	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common Stock, Value, Issued	2	2	2	2	2	2	2	3	3	3	3	3	3	3	3
Additional paid-in capital	3,947	4,201	4,519	5,321	5,777	6,198	6,507	7,157	7,421	7,938	7,894	6,881	7,387	7,450	6,672
Accumulated other comprehensive income (loss)	-1	-1	-1	-0	1	2	21	-12	1	-2	-68	16	1	-14	128
Retained earnings	-3,444	-3,415	-3,522	-3,967	-4,705	-5,262	-5,374	-5,120	-2,989	-1,853	859	3,201	6,523	10,142	9,607
Total shareholders’ equity	504	928	1,196	1,356	1,096	1,094	1,338	2,042	4,435	6,085	8,687	10,100	13,913	17,580	16,410
Total liabilities and shareholders’ equity	1,725	2,204	2,759	2,319	2,335	2,499	2,897	3,546	6,246	8,318	11,752	13,433	18,151	22,730	22,533